Early research studies have shown that although the inhibitor is not upregulated in diffuse astrocytomas, it is upregulated and traceable in isocitrate dehydrogenase (IDH)-wildtype GBM (Figure 2) and high-grade IDH mutant astrocytomas (Figure 3 and Figure 4) [8]. This evidence concerns the gene IDH3A and glioblastoma.